No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.
TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.
Mary E. Brunkow, PhD; Fred Ramsdell, PhD; and Shimon Sakaguchi, PhD, MD, will share the 2025 prize for research that has led to new treatments for autoimmune disease and cancer.
The National Science Foundation (NSF) is setting up seven new institutes for studying foundational AI. Two of the initiatives have healthcare as a prime focus.
Pioneering cardiologist James Muller, MD, a winner of the Nobel Peace Prize, was one of the chief researchers that developed the concept of vulnerable plaques causing heart attacks. He was recently honored by the American College of Cardiology for his contributions.
Teams from three universities have received four-year research grants to examine the relationship between chronic stress and CVD. Each team plans to study the issue from a different angle.
A research lab led by a veteran cardiothoracic surgeon found that ChatGPT—particularly the GPT-4 model—could 'potentially revolutionize' training in the years ahead.
